CHANGE YOUR IMAGE
OF WHAT’S POSSIBLE
We offer comprehensive global imaging services from protocol development to study start-up, conduct, closeout and reporting.
THE LARGEST, ONCOLOGY-FOCUSED iCRO
Ensure Optimal Imaging and Maximize Data
We leverage our imaging expertise to evaluate every measure of efficacy in early Phase trials, and ensure optimal clarifications and/or modifications of criterion in registration trials.
Global Trials With Real-Time Reads and Multiple Criteria
We perform real-time reads for early-stage to global Phase III Trials. We also deploy multiple criteria on each image to maximize data on efficacy.
Combine Imaging Expertise With Leadership in Compliance and Regulatory Approval
Our expertise and industry-leading quality management system (iQMS) help ensure all systems, procedures and data are fully compliant to meet or exceed applicable regulations.
No one better combines imaging technology, expertise and exquisite services from Phase I through Phase III and IV than us.
Imaging Endpoints (IE) is an imaging research and core laboratory that provides comprehensive imaging CRO (iCRO) services and technology solutions throughout the clinical trial process. IE is the largest oncology-focused iCRO globally, and is widely recognized for successfully conducting the industry’s most complex imaging trials. IE’s iCRO experience spans hundreds of successful trials across all phases of development, including some of the most high-profile, global registration trials in the industry.
REVOLUTIONIZING CLINICAL TRIALS WHERE REVOLUTION IS NEEDED
Rapid Detection and Quantification of Response
We leverage the most advanced imaging technologies and customized criterion to rapidly detect, predict and quantify response.
Radiomics + AI = Deep Imaging
We are a global leader in radiomics, utilizing proprietary imaging technologies such as quantitative textural analysis, Al and other advanced tools to develop imaging biomarkers.
Imaging Endpoints at the Forefront of Clinical Trials
April 21, 2022MORE
Fusion of Therapeutics and Optimal Use of Imaging Technologies!
April 7, 2022MORE
Imaging Endpoints Congratulates Novartis on its FDA approval of Locametz® and Pluvicto™ for Selection and Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer
March 31, 2022MORE